Section Arrow
PBYI.NASDAQ
- Puma Biotechnology
Quotes are at least 15-min delayed:2026/01/07 17:05 EST
After Hours
Last
 5.97
-0.12 (-1.97%)
Bid
5.97
Ask
6.5
High 6.09 
Low 5.97 
Volume 1.68K 
Regular Hours (Closed)
Last
 6.09
+0.23 (+3.92%)
Day High 
6.105 
Prev. Close
5.86 
1-M High
6.27 
Volume 
394.32K 
Bid
5.97
Ask
6.5
Day Low
5.785 
Open
5.9 
1-M Low
5.19 
Market Cap 
295.29M 
Currency 美元 
P/E 7.92 
%Yield -- 
10-SMA 5.95 
20-SMA 5.8 
50-SMA 5.36 
52-W High 6.27 
52-W Low 2.575 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
0.74/0.83
Enterprise Value
318.50M
Balance Sheet
Book Value Per Share
2.29
Cash Flow
Cash Flow Yield
0.15
Income Statement
Total Revenue
230.47M
Operating Revenue Per Share
4.55
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.1256+0.0206+19.62%-- 
After Hours 0.127 +0.0014 +1.11%
ERASErasca5.17+1.54+42.42%-- 
After Hours 4.56 -0.61 -11.80%
RXRXRecursion Pharmaceuticals4.86+0.31+6.81%-- 
After Hours 4.8003 -0.0597 -1.23%
VTYXVentyx Biosciences13.73+3.68+36.62%-- 
After Hours 13.74 +0.01 +0.07%
GLUEMonte Rosa Therapeutics23.28+7.27+45.41%54.09PE
After Hours 23.65 +0.37 +1.59%
Industry overview quotes are at least 15 minutes delayed
Business Description
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.